<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>MULTITRACE-4- zinc sulfate heptahydrate, cupric sulfate, manganese sulfate and chromic chloride injection, solution </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>
<span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">-4 (TRACE ELEMENTS INJECTION 4, USP)</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0d8abdd6-58da-4f85-812c-7aa616d838b2"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">FOR IV USE AFTER DILUTION</p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_4e2a969b-f78a-4c17-b896-927b11d56b25"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 (TRACE ELEMENTS INJECTION 4, USP) </span>is a sterile, nonpyrogenic solution containing four Trace Elements for use as an additive for Total Parenteral Nutrition (TPN).</p>
<p>Each mL provides: Zinc 1 mg, Copper 0.4 mg, Manganese 0.1 mg and Chromium 4 mcg. Each mL contains: Zinc Sulfate Heptahydrate 4.39 mg (equivalent to 1 mg Zinc); Cupric Sulfate Pentahydrate 1.57 mg (equivalent to 0.4 mg Copper); Manganese Sulfate Monohydrate 0.308 mg (equivalent to 0.1 mg Manganese); Chromic Chloride Hexahydrate 20.5 mcg (equivalent to 4 mcg Chromium); and Water for Injection, q.s. pH of the solution may be adjusted with sulfuric acid and/or sodium hydroxide. 0.9% Benzyl Alcohol is added as an antimicrobial preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c568e084-e9ef-4940-ade5-59e7ad552493"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First"><span class="Bold">ZINC </span>has been identified as a cofactor for over 70 different enzymes, including alkaline phosphatase, lactic dehydrogenase and both RNA and DNA polymerase. Zinc facilitates <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, helps maintain normal growth rates, normal skin hydration and senses of taste and smell.</p>
<p>Providing zinc during TPN prevents development of the following deficiency symptoms: parakeratosis, <span class="product-label-link" type="condition" conceptid="44783805" conceptname="Hypogeusia">hypogeusia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">dysosmia</span>, geophagia, <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and <span class="product-label-link" type="condition" conceptid="4279681" conceptname="Hepatosplenomegaly">hepatosplenomegaly</span>. At plasma levels below 20 mcg zinc/100 mL, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> followed by <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> has been reported for TPN patients.</p>
<p><span class="Bold">COPPER </span>is essential as a cofactor for serum <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Copper also helps maintain normal rates of red and white blood cell formation. Scorbutic type bone changes seen in infants fed exclusively with copper-poor cow's milk are believed due to <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span> of ascorbate oxidase, a cuproenzyme.</p>
<p>Providing copper during TPN prevents development of the following deficiency symptoms: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, depressed <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span> levels, impaired transferrin formation and secondary <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>.</p>
<p><span class="Bold">MANGANESE </span>is an activator for enzymes such as polysaccharide polymerase, liver arginase, <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> and <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> carboxylase.</p>
<p>Providing manganese during TPN prevents development of the following deficiency symptoms: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and changes in growth and color of hair.</p>
<p><span class="Bold">CHROMIUM </span>(trivalent) is part of glucose tolerance factor, an activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function.</p>
<p>Providing chromium during TPN prevents development of the following deficiency symptoms: impaired glucose tolerance, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and a <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> similar to mild/moderate <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_933a4c32-87d6-4b8a-b66f-3aa41f8a7df1"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">This formulation is indicated for use as a supplement to intravenous solutions given for TPN. Administration of the solution in TPN solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_ffcad1fa-92ff-4be2-9cf0-a5e4324800f2"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 </span>should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>.</p>
<p><span class="Bold">WARNINGS: Copper and Manganese are eliminated via the bile. In patients with severe liver dysfunction and/or biliary tract obstruction, decreasing or omitting copper and manganese supplements entirely may be necessary.</span></p>
<p><span class="Bold">This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</span></p>
<p><span class="Bold">Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_d962eae2-1671-4e62-8edb-c625965d6064"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<p class="First">Before administering <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 </span>in TPN solutions, the physician must assess the metabolic requirements for trace elements and disease state of the patient. Frequent determinations of serum levels of the various trace elements are suggested as a guideline for adjusting the dosage or completely omitting the solution. <span class="Bold">ZINC </span>is eliminated via the intestine and kidneys. The possibility of retention should be considered in patients with malfunctioning excretory routes. <span class="Bold">COPPER </span>and <span class="Bold">MANGANESE </span>are eliminated via the bile, therefore, the possibility of the</p>
<p>retention of these elements should be considered in patients with biliary obstruction. Ancillary routes of <span class="Bold">MANGANESE </span>excretion, however, include pancreatic juice, or reabsorption into the lumen of duodenum, jejunum, or ileum.</p>
<p>In assessing the contribution of <span class="Bold">CHROMIUM </span>supplements to maintenance of normal glucose homeostasis, consideration should be given to the possibility that the patient may be diabetic, in which case oral or intravenous antidiabetic medication may be indicated.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_1f3c011f-d2de-40ab-ac17-d2d2cbf02cc7"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pregnancy
</span></span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_774c9ccf-e1c5-4bf9-9edb-a2fefa7e01af"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects
</span></h3>
<p class="First">Pregnancy Category C: Safety for use in pregnancy has not been established. Use of <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 </span>in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_dd3274fc-1230-4eaa-8050-33edf4a80758"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The amounts of <span class="Bold">ZINC, COPPER, MANGANESE, </span>and <span class="Bold">CHROMIUM </span>in the solution are very small and toxicity symptoms due to these trace elements at suggested dosage level are considered unlikely to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_58dd82ee-8b61-4ea3-9dba-5b3fbe900e5b"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Symptoms of <span class="Bold">ZINC </span><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> resulting from oral ingestion of Zinc Sulfate in large amounts have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Symptoms included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>. Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients without toxic manifestations. Normal plasma levels for Zinc vary from approximately 88 to 112 mcg/100 mL. Plasma levels sufficient to produce symptoms of toxic manifestations are not known. Calcium supplements may confer a protective effect against Zinc toxicity.</p>
<p>Symptoms of <span class="Bold">COPPER </span>toxicity reported in literature include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, behavior change, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, progressive marasmus, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. D-penicillamine has been reported effective as an antidote.</p>
<p><span class="Bold">MANGANESE </span>toxicity has not been reported in patients receiving TPN. Neither have reports of manganese toxicity from excessive intake in foods and/or beverages been published.</p>
<p>Symptoms of <span class="Bold">CHROMIUM </span>toxicity include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and gastrointestinal tract, renal and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span>, and abnormalities of the central nervous system culminating in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Trivalent Chromium administered intravenously to TPN patients has been shown to be nontoxic when given at dosage levels up to 250 mcg/day for two consecutive weeks.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_600292b7-8fcd-4804-ac14-2623ec2bf32c"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Each mL of the solution provides Zinc 1 mg, Copper 0.4 mg, Manganese 0.1 mg, and Chromium 4 mcg. The suggested dosage ranges for the four trace elements are:</p>
<p><span class="Bold"><span class="Italics">ZINC</span></span><span class="Bold">: </span>For the metabolically stable adult receiving TPN, the suggested intravenous dosage level is 2.5 to 4 mg zinc/day. An additional 2 mg zinc/day is suggested for acute catabolic states. For the stable adult with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span> from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended. Frequent monitoring of Zinc blood levels is suggested for patients receiving more than the usual maintenance dosage level of zinc. Normal plasma levels for zinc vary from approximately 88 to 112 mcg/100 mL.</p>
<p>For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg zinc/kg/day is suggested.</p>
<p><span class="Bold"><span class="Italics">COPPER</span></span><span class="Bold">: </span>For the metabolically stable adult receiving TPN, the suggested additive dosage level is 0.5 to 1.5 mg copper/day. For pediatric patients, the suggested additive dosage level is 20 mcg copper/kg/day. The normal plasma range for copper is approximately 80 to 160 mcg/100 mL.</p>
<p><span class="Bold"><span class="Italics">MANGANESE</span></span><span class="Bold">: </span>For the metabolically stable adult receiving TPN, the suggested additive dosage level for manganese is 0.15 to 0.8 mg/day. For pediatric patients, a dosage level of 2 to 10 mcg manganese/kg/day is recommended.</p>
<p><span class="Bold"><span class="Italics">CHROMIUM</span></span><span class="Bold">: </span>For the metabolically stable adult receiving TPN, the suggested additive dosage level is 10 to 15 mcg chromium/day. The metabolically stable adult with intestinal <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span> may require 20 mcg chromium/day with frequent monitoring of blood levels as a guideline for subsequent administration. For pediatric patients, the suggested additive dosage level is 0.14 to 0.20 mcg/kg/day.</p>
<p>Periodic monitoring of plasma levels of Zinc, Copper, Manganese, and Chromium is suggested as a guideline for administration.</p>
<p>Aseptic addition of the solution to the TPN solution under a laminar flow hood is recommended. The trace elements present in the solution are physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.</p>
<p>Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_126a9f7b-3297-4628-af8c-5f41b6d8cc36"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">- 4 (TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p>Each mL provides: Zinc 1 mg, Copper 0.4 mg, Manganese 0.1 mg and Chromium 4 mcg.</p>
<p>NDC 0517-7410-25              10 mL Multiple Dose Vial*              Packaged in boxes of 25</p>
<p>*Contains 0.9% benzyl alcohol as an antimicrobial preservative.</p>
<p><span class="Bold">AMERICAN<br></span><span class="Bold">REGENT, INC.<br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
<p>IN7410<br>Rev. 1/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_c927e854-37f1-4c11-bdef-fc259834d890"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL </span></h1>
<p class="First"><span class="Bold"><span class="Underline">Container<br><br></span></span></p>
<p><span class="Bold"><span class="Bold">NDC 0517-7410-25</span><br><br>MULTITRACE<span class="Sup">®</span>-4<br>(TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p><span class="Bold">10 mL <br>MULTIPLE DOSE VIAL</span></p>
<p>FOR IV USE AFTER DILUTION</p>
<p><span class="Bold">Rx Only<br><br>AMERICAN<br>REGENT, INC.<br></span>SHIRLEY, NY  11967<br><span class="Bold"><br><img alt="Container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4efe7e7-649b-484f-a27b-26485a12626b&amp;name=multitrace-4-1.jpg"></span></p>
<p><span class="Bold"><span class="Underline"><br>Carton</span></span></p>
<p><span class="Bold">MULTITRACE<span class="Sup">®</span>-4<br>(TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p><span class="Bold">NDC 0517-7410-25<br>25 x 10 mL<br>MULTIPLE DOSE VIALS</span></p>
<p><span class="Bold">FOR IV USE AFTER DILUTION</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each mL provides: Zinc 1 mg, Copper 0.4 mg, Manganese 0.1 mg, Chromium 4 mcg. Each mL contains: Zinc Sulfate (Heptahydrate) 4.39 mg, Cupric Sulfate (Pentahydrate) 1.57 mg, Manganese Sulfate (Monohydrate) 0.308 mg, Chromic Chloride (Hexahydrate) 20.5 mcg, Benzyl Alcohol 0.9% as an antimicrobial preservative, and Water for Injection q.s. pH may be adjusted with Sulfuric Acid and/or Sodium Hydroxide. Sterile, nonpyrogenic.<br>Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature).<br>Directions for Use: See Package Insert.</p>
<p><span class="Bold">AMERICAN REGENT, INC.</span><br>SHIRLEY, NY 11967</p>
<p>Rev. 11/05<br><br></p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4efe7e7-649b-484f-a27b-26485a12626b&amp;name=multitrace-4-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MULTITRACE-4 		
					</strong><br><span class="contentTableReg">trace elements 4 injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-7410</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZINC SULFATE HEPTAHYDRATE</strong> (ZINC CATION) </td>
<td class="formItem">ZINC CATION</td>
<td class="formItem">4.39 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CUPRIC SULFATE</strong> (CUPRIC CATION) </td>
<td class="formItem">CUPRIC CATION</td>
<td class="formItem">1.57 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANGANESE SULFATE</strong> (MANGANESE CATION (2+)) </td>
<td class="formItem">MANGANESE CATION (2+)</td>
<td class="formItem">0.308 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CHROMIC CHLORIDE</strong> (CHROMIC CATION) </td>
<td class="formItem">CHROMIC CATION</td>
<td class="formItem">20.5 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-7410-25</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">02/17/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Luitpold Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">002033710</td>
<td class="formItem">ANALYSIS(0517-7410), MANUFACTURE(0517-7410), STERILIZE(0517-7410)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6817d524-2100-4c8e-91c2-d1d2d999f31a</div>
<div>Set id: a4efe7e7-649b-484f-a27b-26485a12626b</div>
<div>Version: 2</div>
<div>Effective Time: 20140902</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
